Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan

BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Cuppini, Lucia, Calleri, Angelica, Bruzzone, Maria Grazia, Prodi, Elena, Anghileri, Elena, Pellegatta, Serena, Mancuso, Patrizia, Porrati, Paola, Di Stefano, Anna Luisa, Ceroni, Mauro, Bertolini, Francesco, Finocchiaro, Gaetano, Eoli, Marica
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3772091/
https://ncbi.nlm.nih.gov/pubmed/24069296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0074345
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires